Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can your Brain's expectations fool you? Parkinson's hallucination study seeks answers

NCT ID NCT07427498

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study will examine whether prior expectations increase false perceptions in Parkinson's patients who experience visual hallucinations. About 60 participants, including patients with and without hallucinations and healthy volunteers, will complete a computer-based face detection task and cognitive tests. The goal is to better understand the mechanisms behind hallucinations in Parkinson's disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help explain why some Parkinson's patients experience hallucinations, potentially guiding future therapies.
What could go wrong
This is an early observational study with only 60 participants, so results may not apply broadly. It does not test any treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will recruit Parkinson's disease patients (disease duration ≥1 year, no major cognitive impairment) from CHU Grenoble-Alpes, including 15 with minor hallucinations (e.g., passage/presence sensations) and 15 with major hallucinations (e.g., complex visual hallucinations). Patients with active psychosis are excluded. Healthy volunteers (matched by age, gender, and education) will be recruited via ads in senior associations and affiliated institutions (CHUGA, GIN). Matching tolerates ±5 years for age and ±2 years for education; those without a high school diploma will be matched without strict education criteria. Ads may also appear on institutional websites.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults diagnosed with Parkinson's disease (with or without visual hallucinations) or healthy volunteers. * Age 18 - 85 years. * Consent to participate. Exclusion Criteria: * Currently participating in another clinical or therapeutic trial involving the testing of a drug treatment. * Inability to perform cognitive tests due to: Non-psychiatric (somatic) conditions likely to affect cognitive abilities. Peripheral sensory or motor deficits. Acute clinical conditions (e.g., agitation, impaired consciousness). * Diagnosis of dementia. * Individuals covered by Articles L1121-5 to L1121-8 of the French Public Health Code (Code de la Santé Publique), including: Pregnant women, women in labor, or breastfeeding mothers. Individuals deprived of liberty by judicial or administrative decision. Individuals receiving psychiatric care under Articles L. 3212-1 and L. 3213-1 (excluding those covered by Article L. 1121-8). Individuals admitted to a healthcare or social institution for purposes other than research. Minors or adults under legal guardianship or unable to express consent. \- Individuals with a hierarchical relationship to any professional involved in the study. Only for healthy volunteers: \- Personal history of diagnosed neurological disorders. Post-Inclusion Exclusion: \- Participants included in the study but found to have a MoCA score below 24 will be excluded from the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease (disorder) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hallucinations Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Grenoble University Hospitals

    La Tronche, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.